Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326767461> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2326767461 endingPage "375" @default.
- W2326767461 startingPage "370" @default.
- W2326767461 abstract "This phase I study is designed to determine the maximal tolerated dose and the dose-limiting toxicity of docetaxel with cisplatin and concurrent radiotherapy in patients with unresectable locally advanced gastric adenocarcinoma. Docetaxel was given once a week with the dosage escalated from 5 mg/m(2) to 15 mg/m(2) in increments of 2.5 mg/m(2). Cisplatin were administered at 20 mg/m(2) once a week. Radiotherapy was delivered to 50.4Gy at 1.8Gy/day. At least three patients were enrolled at each level. The maximal tolerated dose (MTD) and dose-limiting toxicity (DLTs) was determined. The DLTs were defined as grade 3 or 4 hematologic and nonhematologic toxicity. Twenty-one patients with locally advanced gastric adenocarcinoma were enrolled. Grade 1-2 neutropenia and nausea/vomiting were the most common side effects. The first DLT (grade-3 neutropenia) was observed in one of three patients at 12.5 mg/m(2) docetaxel. Three more patients were enrolled, but DLT was not observed and 6 patients were enrolled into 15 mg/m(2) group, DLT occurred in 3 patients (1 Grade 3 neutropenia, 1 Grade 4 neutropenia and 1 Grade 3 nausea/vomiting). Overall tumor response rate was 66.7% with 28.6% complete and 38.1% partial response. In conclusion, the MTD of docetaxel was 15 mg/m(2), and the recommended dose of docetaxel for Phase II study was 12.5 mg/m(2) weekly. The docetaxel and cisplatin with concurrent radiotherapy were tolerable and feasible in treating locally advanced gastric adenocarcinoma." @default.
- W2326767461 created "2016-06-24" @default.
- W2326767461 creator A5001774854 @default.
- W2326767461 creator A5003594133 @default.
- W2326767461 creator A5007244401 @default.
- W2326767461 creator A5024090635 @default.
- W2326767461 creator A5026771806 @default.
- W2326767461 creator A5027664020 @default.
- W2326767461 creator A5058101064 @default.
- W2326767461 creator A5075442794 @default.
- W2326767461 date "2012-01-01" @default.
- W2326767461 modified "2023-10-11" @default.
- W2326767461 title "Phase I study of docetaxel, cisplatin and concurrent radiotherapy for locally advanced gastric adenocarcinoma" @default.
- W2326767461 doi "https://doi.org/10.4149/neo_2012_048" @default.
- W2326767461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22489691" @default.
- W2326767461 hasPublicationYear "2012" @default.
- W2326767461 type Work @default.
- W2326767461 sameAs 2326767461 @default.
- W2326767461 citedByCount "1" @default.
- W2326767461 countsByYear W23267674612022 @default.
- W2326767461 crossrefType "journal-article" @default.
- W2326767461 hasAuthorship W2326767461A5001774854 @default.
- W2326767461 hasAuthorship W2326767461A5003594133 @default.
- W2326767461 hasAuthorship W2326767461A5007244401 @default.
- W2326767461 hasAuthorship W2326767461A5024090635 @default.
- W2326767461 hasAuthorship W2326767461A5026771806 @default.
- W2326767461 hasAuthorship W2326767461A5027664020 @default.
- W2326767461 hasAuthorship W2326767461A5058101064 @default.
- W2326767461 hasAuthorship W2326767461A5075442794 @default.
- W2326767461 hasBestOaLocation W23267674611 @default.
- W2326767461 hasConcept C121608353 @default.
- W2326767461 hasConcept C126322002 @default.
- W2326767461 hasConcept C143998085 @default.
- W2326767461 hasConcept C2776694085 @default.
- W2326767461 hasConcept C2777063308 @default.
- W2326767461 hasConcept C2778239845 @default.
- W2326767461 hasConcept C2780580376 @default.
- W2326767461 hasConcept C2780852908 @default.
- W2326767461 hasConcept C2781182431 @default.
- W2326767461 hasConcept C2781190966 @default.
- W2326767461 hasConcept C29730261 @default.
- W2326767461 hasConcept C31760486 @default.
- W2326767461 hasConcept C509974204 @default.
- W2326767461 hasConcept C71924100 @default.
- W2326767461 hasConcept C90924648 @default.
- W2326767461 hasConceptScore W2326767461C121608353 @default.
- W2326767461 hasConceptScore W2326767461C126322002 @default.
- W2326767461 hasConceptScore W2326767461C143998085 @default.
- W2326767461 hasConceptScore W2326767461C2776694085 @default.
- W2326767461 hasConceptScore W2326767461C2777063308 @default.
- W2326767461 hasConceptScore W2326767461C2778239845 @default.
- W2326767461 hasConceptScore W2326767461C2780580376 @default.
- W2326767461 hasConceptScore W2326767461C2780852908 @default.
- W2326767461 hasConceptScore W2326767461C2781182431 @default.
- W2326767461 hasConceptScore W2326767461C2781190966 @default.
- W2326767461 hasConceptScore W2326767461C29730261 @default.
- W2326767461 hasConceptScore W2326767461C31760486 @default.
- W2326767461 hasConceptScore W2326767461C509974204 @default.
- W2326767461 hasConceptScore W2326767461C71924100 @default.
- W2326767461 hasConceptScore W2326767461C90924648 @default.
- W2326767461 hasIssue "04" @default.
- W2326767461 hasLocation W23267674611 @default.
- W2326767461 hasLocation W23267674612 @default.
- W2326767461 hasOpenAccess W2326767461 @default.
- W2326767461 hasPrimaryLocation W23267674611 @default.
- W2326767461 hasRelatedWork W2023246694 @default.
- W2326767461 hasRelatedWork W2100029565 @default.
- W2326767461 hasRelatedWork W2104532118 @default.
- W2326767461 hasRelatedWork W2243375749 @default.
- W2326767461 hasRelatedWork W2324380568 @default.
- W2326767461 hasRelatedWork W2406976129 @default.
- W2326767461 hasRelatedWork W2412619742 @default.
- W2326767461 hasRelatedWork W2417881752 @default.
- W2326767461 hasRelatedWork W2891028327 @default.
- W2326767461 hasRelatedWork W57680343 @default.
- W2326767461 hasVolume "59" @default.
- W2326767461 isParatext "false" @default.
- W2326767461 isRetracted "false" @default.
- W2326767461 magId "2326767461" @default.
- W2326767461 workType "article" @default.